Literature DB >> 10387093

Characterization and crystallization of soluble human Fc gamma receptor II (CD32) isoforms produced in insect cells.

P Sondermann1, U Jacob, C Kutscher, J Frey.   

Abstract

Fc gamma RII (CD32), the receptor for the Fc part of IgG, is responsible for the clearance of immunocomplexes by macrophages and plays a role in the regulation of antibody production by B cells. To investigate the process of immunocomplex binding in terms of stoichiometry and stability of the Fc gamma RII:IgG complex, we produced both Fc gamma RII isoforms (Fc gamma RIIa and Fc gamma RIIb) as soluble proteins in insect cells. The expressed proteins could be purified in high yields and were biologically active as judged by their ability to bind IgG. Thus, the minor glycosylation performed by the insect cells is not crucial for the binding of the usually highly glycosylated Fc gamma RII to IgG. The dissociation constant of the sFc gamma RIIa:IgG-hFc complex was determined by fluorescence titration (KD = 2.5 x 10(-)7 M). Complementary sFc gamma RIIa antagonizes immunocomplex binding to B cells. Here sFc gamma RIIa showed a comparable dissociation constant (KD = 1.7 x 10(-)7 M) which was almost 10-fold lower than the constant for Fc gamma RIIb. The stoichiometry of the FcRIIa:IgG-hFc complex was determined by equilibrium gel filtration and shows that IgG is able to bind alternatively one or two Fc gamma RII molecules in a noncooperative manner. Furthermore, in an ELISA-based assay the isotype specificity of various anti-Fc gamma RII monoclonal antibodies was measured as well as their ability to interfere with the IgG recognition through its receptors. To further investigate the molecular basis of the Fc gamma RII-ligand interaction, we crystallized Fc gamma RIIb. Trigonal crystals diffracted to 3 A and the structure solution is in progress.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10387093     DOI: 10.1021/bi982889q

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

Review 1.  Regulation of antibody effector functions through IgG Fc N-glycosylation.

Authors:  Isaak Quast; Benjamin Peschke; Jan D Lünemann
Journal:  Cell Mol Life Sci       Date:  2016-09-17       Impact factor: 9.261

2.  Characterization of low affinity Fcγ receptor biotinylation under controlled reaction conditions by mass spectrometry and ligand binding analysis.

Authors:  Karin P M Geuijen; David F Egging; Stefanie Bartels; Jan Schouten; Richard B Schasfoort; Michel H Eppink
Journal:  Protein Sci       Date:  2016-08-19       Impact factor: 6.725

3.  Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection.

Authors:  S C Kim; W Wakwe; L B Higginbotham; D V Mathews; C P Breeden; A C Stephenson; J Jenkins; E Strobert; K Price; L Price; R Kuhn; H Wang; A Yamniuk; S Suchard; A B Farris; T C Pearson; C P Larsen; M L Ford; A Suri; S Nadler; A B Adams
Journal:  Am J Transplant       Date:  2017-02-25       Impact factor: 8.086

4.  Functional interactions of HslV (ClpQ) with the ATPase HslU (ClpY).

Authors:  Ravishankar Ramachandran; Claudia Hartmann; Hyun Kyu Song; Robert Huber; Matthias Bochtler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

Review 5.  A perspective on the structure and receptor binding properties of immunoglobulin G Fc.

Authors:  Quinlin M Hanson; Adam W Barb
Journal:  Biochemistry       Date:  2015-05-07       Impact factor: 3.162

Review 6.  The FcγR/IgG Interaction as Target for the Treatment of Autoimmune Diseases.

Authors:  Peter Sondermann
Journal:  J Clin Immunol       Date:  2016-04-02       Impact factor: 8.317

7.  Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP).

Authors:  Y Machino; H Ohta; E Suzuki; S Higurashi; T Tezuka; H Nagashima; J Kohroki; Y Masuho
Journal:  Clin Exp Immunol       Date:  2010-10-05       Impact factor: 4.330

Review 8.  Fc gamma receptors: glycobiology and therapeutic prospects.

Authors:  Jerrard M Hayes; Mark R Wormald; Pauline M Rudd; Gavin P Davey
Journal:  J Inflamm Res       Date:  2016-11-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.